PCORI Awards Mercy Funding To Expand Its AI-Driven Smart-Texting Program

The Patient-Centered Outcomes Research Institute (PCORI), through its Health Systems Implementation Initiative, approved Mercy for a four-year funding award to expand its artificial intelligence (AI)-driven, electronic, consumer-reported monitoring platform, the Chen Chemotherapy Model. The amount awarded was not stated. The platform is offered to adults aged 18 and older who are undergoing chemotherapy for cancer. The expanded program is expected to be available to consumers in October 2026.

With this new funding, Mercy will expand access to the Chen Chemotherapy Model to a broader age group. The platform will be enhanced as follows:

Include more diagnoses . . .